Low 25(OH) D serum levels are related with hip fracture in postmenopausal women: a matched case–control study by Xing-Mao Fu et al.
Fu et al. J Transl Med  (2015) 13:388 
DOI 10.1186/s12967-015-0756-x
RESEARCH
Low 25(OH) D serum levels are related 
with hip fracture in postmenopausal women: a 
matched case–control study
Xing‑Mao Fu*†, Shao‑Guang Fan†, Shu‑Liang Li, Yi‑Sheng Chen, Hai Wu and Yan‑Long Guo
Abstract 
Purpose: There is limited information on the prevalence of vitamin D deficiency among patients diagnosed with 
hip fracture in the Chinese Han population. Therefore, the aim of this study was to assess the effects of change in 
the serum levels of 25‑hydroxyvitamin D [25(OH) D] and intact parathyroid hormone (iPTH) among postmenopausal 
women in North China with confirmed hip fracture.
Methods: This study was done from May 1, 2012 to April 30, 2014. Three hundred and forty‑nine postmenopausal 
women who were diagnosed with first‑ever hip fracture and 349 matched controls without fracture were used for 
this study. The 25(OH) D, iPTH, alkaline phosphatase, calcium, and phosphorus levels were measured in fasting venous 
blood samples collected from the subjects. A predesigned questionnaire was used to collect information on covari‑
ates for multivariate analyses to evaluate the hypothesized relationship between vitamin D deficiency and fracture 
risk.
Results: The serum 25(OH) D levels were found to be significantly (P < 0.0001) lower in hip fracture patients than 
in the controls [37.0 (interquartile range [IQR] 28.0–48.0) nmol/L vs. 41.3 (IQR 32.0–54.5) nmol/L; P < 0.0001], and 
the iPTH levels were significantly higher in the former group [10.2 (IQR 6.3–14.9) pmol/L vs. 5.8 (IQR 4.1–6.6) pmol/L; 
P < 0.0001]. Further, a 25(OH) D level ≤50 nmol/L was found to independently indicate the occurrence of hip fracture 
[odds ratio (OR), 3.023; 95 % confidence interval (CI) 2.154–4.298], as well as hip fracture with concomitant upper 
limb fracture (OR 4.473; 95 % CI 2.984–10.532). Similarly, a serum iPTH level ≥6.8 pmol/L independently indicated 
the development of hip fracture (OR 2.498; 95 % CI 1.764–3.942), as well as hip fracture with concomitant upper limb 
fracture (OR 3.254; 95 % CI 1.998–7.984).
Conclusions: Vitamin D insufficiency and secondary hyperparathyroidism were found to be common problems in 
the sample of postmenopausal women who had experienced hip fracture. Monitoring the alterations in the serum 
levels of 25(OH) D and iPTH could be applied clinically as independent risk factors for hip fracture.
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Background
Vitamin D deficiency is a common medical condi-
tion worldwide. It usually develops because of insuffi-
cient sources of endogenous and exogenous vitamin D 
(inadequate intake or excessive consumption) and may 
eventually result in bone mass reduction, especially in 
elderly women [1]. The effect of inadequate vitamin D sup-
ply on bone health has been well established, as observed 
in the development of rickets in children and osteomalacia 
in adults [2]; both conditions that result from vitamin D 
deficiency. Age is a predominant risk factor for the devel-
opment of hip fracture and the rapidly increasing number 
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implementing timely and suitable prevention strategies for 
patients with confirmed hip fracture.
A strong association between vitamin D deficiency and 
fracture development has been suggested, and thought to 
underlie the significant increases in mortality and mor-
bidity rates of fracture patients [3, 4]. Even survivors of 
this condition have been reported to be at high risk of 
permanent disability. Rehabilitation results have not been 
optimistic, with almost a quarter of the patients unable 
to live independently and requiring long-term in-home 
supportive nursing care, and over three-fifths of these 
individuals unable to fully recover the same level of leg 
function prior to the fracture [5]. Vitamin D status is 
typically determined by measuring serum 25-hydroxyvi-
tamin D [25(OH) D] levels. Piepe et al. [6] found that in 
elderly patients who had recently experienced hip frac-
ture, vitamin D insufficiency was a commonly detected 
phenomenon and not a coincidental finding. Previous 
works have documented negative correlations between 
decreased serum levels of 25(OH) D and increased risk of 
hip fracture [7–9]. For example, in Japan, a recent study 
conducted at a general hospital found that about two-
thirds of patients with acute hip fracture had vitamin D 
insufficiency [10]. In addition, previous studies have sug-
gested that lower levels of 25(OH) D could be regarded as 
a risk marker for hip fracture [11, 12]. Given this correla-
tion between low vitamin D level and increased risk for 
hip fracture, Lips et al. [13] reported that a daily vitamin 
D supplement of 800 IU in combination with calcium was 
an effective method to reduce the high incidence of non-
vertebral fracture. The efficacy of vitamin D in prevent-
ing fractures could stem from its effects on muscle tissue 
(maintaining the normal structural and optimal functions 
of skeletal muscles), in addition to its known benefits in 
bone metabolism [14].
Hip fractures are estimated to account for a large pro-
portion of osteoporosis cases, along with other severe 
consequences. A single fall is associated with both hip 
and upper limb fractures in about 4–5  % of older peo-
ple who fracture their hip [15, 16]. Several reports have 
shown that decreased levels of 25(OH) D lead to the 
occurrence of hip and other fragility fractures, including 
those affecting the upper limbs; however, there are incon-
sistencies among the different studies [17]. In research 
conducted in India, Dhanwal et  al. [18] found that hip 
fracture patients frequently had higher rates of vitamin D 
deficiency and secondary hyperparathyroidism. Unfortu-
nately, no similar studies have been done in a sample of 
Chinese patients. Therefore, the aim of this preliminary 
study was to evaluate the serum 25(OH) D and intact 
parathyroid hormone (iPTH) levels in postmenopausal 
women diagnosed with hip fracture in the northern Chi-
nese Han population.
Subjects and methods
The study protocol was approved by the ethics committee 
of the 89th Hospital of People’s Liberation Army and was 
explained to all the participants included in the study. 
Written informed consent was obtained from eligible 
subjects in accordance with the Declaration of Helsinki.
From May 1, 2012 to April 30, 2014, participants 
were recruited at the Department of Orthopedics of the 
89th Hospital of People’s Liberation Army (situated at 
39°26′N latitude). The hospital is one of the best ortho-
pedic hospitals in Shandong Province, China. Annually, 
the number of orthopedic outpatients is approximately 
20,000 patients (the number seen in the hospital). In fact, 
the hospital receives a particular group of patients with 
complications. The inclusion criterion was predefined 
as postmenopausal women with confirmed first-ever 
hip fracture. The exclusion criteria included: (1) patients 
diagnosed with a fracture after a high-energy trauma, 
such as vehicular accidents, major falls, and direct inju-
ries, among others; (2) patients with confirmed second-
ary tumor or primary hyperparathyroidism; (3) patients 
with other metabolic disorders or internal disease, such 
as hyperthyroidism, malignant tumor, chronic kidney 
disease, as well as autoimmune diseases; (4) patients 
taking calcium and/or vitamin D supplements. Among 
the patients with fractures were a subgroup consisting 
of subjects who sustained a concomitant fracture of the 
upper limb. In this subgroup, a single fall resulted in both 
a hip and an upper limb fracture. All the fractures were 
confirmed by X-ray examination, and all X-rays examina-
tions were done by the same radiologist.
Postmenopausal women absent of hip fracture matched 
in age (±1  year), ethnicity, body mass index (BMI ±1), 
and common chronic diseases (hypertension, diabe-
tes mellitus, hyperlipoproteinemia, and cardiovascular 
disease) were included as a control group. The controls 
came from a community located around the hospital. It 
was a random population sample. All control subjects 
were physically active (at work or able to perform home 
duties) within 30  days of the date of fracture diagnosis 
in the patient. If more than one potential control met 
the criteria, the control whose date of serum collection 
was closest to that of the patient was selected. Women 
who took calcium and/or vitamin D supplements were 
excluded. The exclusion criteria for patients also applied 
to the controls. Subjects who previously received estro-
gen treatment or other bone-active therapies were 
excluded from both the experimental and control groups.
A standardized questionnaire was predesigned to 
explore the hypothesized relationship between risk fac-
tors for fractures and vitamin D deficiency. At admission, 
all women (patients and controls) were instructed to 
answer the standardized questionnaire, which collected 
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information on age, BMI, current tobacco use, season at 
time of blood collection, sun exposure (“adequate” was 
defined as over 15–20 min daily for 5 days per week or 
>2 h per week) [19], history of a fall in the last year, hip 
fracture type (cervical or trochanteric), cognitive impair-
ment, neurologic impairment, infections, time between 
fracture occurrence and blood collection, number of 
concomitant diseases, surgical procedure type (arthro-
plasty or internal fixation), and family history of fragility 
fracture. Cognitive impairment was based mainly on the 
evaluation of the Mini-Mental State Examination score 
(24/30) [20]. Cognitive impairment was predefined as a 
score of less than 24 [21]. After the completion of records 
and careful evaluation of the patients’ information, neu-
rologic disease-related impairments were examined and 
confirmed by clinical examination.
On the morning (8:00 AM) after the day of admission, 
fasting blood samples were obtained from all women 
(patients and controls) for the determination of serum 
25(OH) D and iPTH levels. Blood samples (5  mL in 
total) were drawn from the cubital vein of each subject 
with the use of vacuum collection tubes. The collected 
serum samples were centrifuged for 10 min, then aliquots 
of the samples were refrigerated immediately at −80  °C 
until use. All the tests were done under the supervision 
of a qualified biochemist. The serum levels of calcium, 
phosphorous, high-sensitivity C-reactive protein (Hs-
CRP) and alkaline phosphatase (ALP) were estimated by 
standard procedure with the use of an Olympus AU2700 
analyzer (Olympus, Tokyo, Japan). The serum 25(OH) 
D levels were measured within the calibration range 
(7.5–175 nmol/L) by applying the E601 modular analyt-
ics (Roche Diagnostics, Mannheim, Germany). The intra-
assay and inter-assay coefficients of variation (CV) were 
4.6–7.9 and 5.8–9.7 %, respectively. The level of 25(OH) 
D was used to classify the vitamin D status as: (1) vitamin 
D deficiency (<50 nmol/L) or (2) vitamin D insufficiency 
(50–75  nmol/L) [22]. The chemiluminescence immuno-
assay method was used to detect the specific serum levels 
of iPTH with the use of the DPC Immulite 2000 system 
(Diagnostic Products Corporation, Los Angeles, CA, 
USA) within a calibration range of 0.3–263 pmol/L; the 
sensitivity of the method was 0.3 pmol/L. The intra-assay 
CV ranged from 2.88 to 3.93 %, whereas the inter-assay 
CV ranged from 3.89 to 5.02 %. The normal range based 
on laboratory standards is 1.3–6.8 pmol/L.
In this study, discrete variables are expressed as pro-
portions or frequencies; these were compared by using 
the Chi square test between groups. Continuous vari-
ables are expressed as medians with an interquartile 
range (IQR); between-groups comparisons were done 
with the Mann–Whitney test or Student’s paired t test. 
Besides, Spearman’s test was applied to analyze specific 
correlations among continuous variables. Individual clin-
ical information (age, BMI, current tobacco use, season 
of blood collection, sun exposure, history of a fall in the 
last year, hip fracture type, cognitive impairment, neu-
rologic impairment, infections, time between fracture 
occurrence and blood collection, number of concomitant 
diseases, surgical procedure type and family history of 
fragility fracture) and other blood biomarkers (calcium, 
phosphorous, Hs-CRP and ALP) collected previously 
were measured as binary variables. Conditional logistic 
regression analysis was applied to determine the asso-
ciation between risk of fracture and alterations in serum 
25(OH) D levels, after adjustment for possible confound-
ers, namely, age, inadequate sun exposure, history of 
falls during the last year, neurologic impairment, cogni-
tive impairment, and serum levels of Hs-CRP, ALP and 
iPTH. Experimental results on the relationship between 
changes in serum levels of 25(OH) D and the occurrence 
of fractures are expressed as adjusted odds ratios (OR) 
and 95 % confidence intervals (CI). Further, the receiver 
operating characteristic (ROC) curves were used in the 
evaluation of the accuracy of serum 25(OH) D levels in 
predicting fracture occurrences. The area under the ROC 
curve (AUC) was calculated as a measure of the accuracy 
of the test. Statistical significance was set at P < 0.05. All 
statistical analyses were done with the use of SPSS for 
Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
From the initial 424 screened patients, 349 postmeno-
pausal women were included in the study. Thirty-three 
cases diagnosed with hip fracture were excluded due to 
a major trauma or cancer affecting the bone, which con-
tributed to the fractures; another 42 cases were excluded 
because of death or halfway transferring to other hos-
pital. The median age of the sample was 64  years (IQR 
55–74  years). The median time between fracture onset 
and blood collection was 17.9 h (IQR 11.2–14.6 h). None 
of the patients received treatment for osteoporosis before 
the fracture. One hundred and twenty-nine patients 
had associated comorbid illnesses, 88 had two or more 
comorbid illnesses, and the rest had a single comorbid 
illness (24.6 % of the patients with hypertension, 16.6 % 
with diabetes, 21.8  % with hyperlipoproteinemia and 
12.9 % with cardiovascular disease). Among the patients, 
16.0 % had a previous family history of fragility fractures, 
and 28.7  % reported receiving treatment for comorbid 
conditions [14.3 % of the patients received glucose low-
ering agent (4.3  % with thiazolidinedione, while 6.3  % 
with insulin), 22.6 % received antihypertensive drugs and 
17.2  % used of lipid-lowering medication]. Among the 
349 eligible patients in our study, 71.3 % of those with hip 
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fracture were confirmed to have vitamin D deficiency, 
whereas 63.6 % was found to have a tendency for second-
ary hyperparathyroidism. Moreover, the incidences in the 
controls were 45.8 and 35.8 %, respectively. Table 1 pre-
sents the summary statistics for the subjects included in 
the study.
Main results
The serum 25(OH) D levels were found to be signifi-
cantly (P  <  0.0001) lower in hip fracture patients than 
in the controls, with an apparent statistical difference 
[37.0 (IQR 28.0–48.0) nmol/L vs. 41.3 (IQR 32.0–54.5) 
nmol/L; P < 0.0001]. Furthermore, there was an obvious 
difference in serum iPTH levels between groups, with 
significantly higher levels in patients than in the con-
trols [10.2 (IQR 6.3–14.9) pmol/L vs. 5.8 (IQR 4.1–6.6) 
pmol/L; P < 0.0001]. As shown in Fig. 1, the Spearman’s 
test results indicated a negative relationship between 
the serum levels of 25(OH) D and iPTH in hip frac-
ture patients (r  =  −0.427, P  <  0.0001). Similarly, there 
Table 1 Baseline characteristics of patients with hip fracture and controls
Results are expressed as percentages or as medians (IQR)
NS no significant, BMI body mass index, MMSE Mini-Mental State Examination score, Hs-CRP high-sensitivity-C-reactive protein (BMI), ALP alkaline phosphatase, iPTH 
intact parathyroid hormone
Parameters Patients (n = 349) Controls (n = 349) P
Age (years), median (IQR) 64 (55–74) 64 (55–74) NS
BMI (kg/m2, IQR) 25.7 (23.5–27.4) 25.8 (23.4–27.5) NS
Smoker (%) 22.9 21.5 NS
Inadequate sun exposure (%) 53.0 30.9 <0.001
Season of blood collection (winter, %) 25.5 25.8 NS
History of falls during the last year, median (IQR) 3 (2–4) 1 (0–2) 0.018
Hip fracture type (%) –
 Femoral head fracture 47.3
 Femoral neck fracture 44.4
 Subtrochanteric 8.3
Concomitant upper‑limb fractures (%) 8.3 –
 Distal radius (%) 5.7 –
 Proximal humerus (%) 2.6 –
Patients had associated comorbid illnesses (%) 37.0 37.0 NS
 Diabetes 16.6 16.3 NS
 Hypertension 24.6 25.2 NS
 Cardiovascular disease 12.9 12.6 NS
 Hyperlipoproteinemia 21.8 21.8 NS
Receiving treatment for comorbid conditions (%) 28.7 28.4 NS
 Glucose treatment 14.3 13.8 NS
 Blood pressure treatment 22.6 21.5 NS
 Use of lipid‑lowering medication 17.2 16.3 NS
MMSE < 24 (%) 22.1 10.0 0.025
Neurologic impairment (%) 18.9 8.3 0.027
Time between fracture and blood collection (hs) median (IQR) 17.9 (11.2–24.6) –
Hospital stay (days), median (IQR) 13 (8–19) –
Laboratory findings (IQR)
 Serum calcium (mmol/L) 2.39 (2.25–2.47) 2.48 (2.32–2.62) 0.032
 Serum phosphate (mmol/L) 1.49 (1.13–1.76) 1.51 (1.20–1.77) NS
 Serum ALP (IU/L) 246 (145–342) 159 (100–236) <0.001
 Serum Hs‑CRP (mg dL−1) 0.36 (0.22–0.42) 0.29 (0.18–0.36) 0.002
 Serum iPTH (pmol/L) 10.2 (6.3–14.9) 5.8 (4.1–6.6) <0.0001
 Serum 25(OH) D (nmol/L) 37.0 (28.0–48.0) 41.3 (32.0–54.5) <0.0001
Vitamin D deficiency [n (%)] 71.3 45.8 <0.0001
Hyperparathyroidism [n (%)] 63.6 35.8 <0.0001
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was also a negative relationship between the serum 
levels of 25(OH) D and iPTH in controls (r  =  −0.301, 
P < 0.0001). In addition, there were significant, although 
weak, correlations between the 25(OH) D levels and 
those of high-sensitivity C-reactive protein (r = −0.162, 
P = 0.002) and Ca (r = 0.202, P < 0.0001) in hip fracture 
patients. Interestingly, there was a negative relationship 
between the serum levels of 25(OH) D and the number 
of falls in hip fracture patients (r = −0.532, P < 0.0001), 
while a similarly negative relationship was found in con-
trols (r = −0.356, P < 0.0001). Blood samples were taken 
over the course of the four seasons and the serum levels 
of 25(OH) D were compared between groups. Analysis 
of variance revealed significant seasonal differences in 
25(OH) D levels (P =  0.003). The patients who entered 
the study during the winter had lower serum levels of 
25(OH) D than the patients who entered the study dur-
ing the other three seasons [35.4 (IQR 25.7–44.6) nmol/L 
vs. 38.2 (IQR 29.2–49.6) nmol/L; P < 0.0001]. No correla-
tions were found between the serum levels of 25(OH) D 
and the remaining binary variables (all, P > 0.05).
25(OH) D and risk of hip fracture
Based on the ROC curve for the screening of hip fracture 
risks, the optimal cutoff level of serum 25(OH) D was 
estimated to be 48.0  nmol/L, which yielded a sensitiv-
ity of 70.6 % and a specificity of 72.3 % (AUC 0.701; 95 % 
CI 0.624–0.779). Table 2 shows that after adjustment for 
Fig. 1 Correlation between the serum 25(OH) D levels and iPTH in 
postmenopausal women with hip fractures (n = 349). iPTH intact 
parathyroid hormone
Table 2 Univariate and multivariate conditional logistic regression analysis for hip and upper-limb fracture
OR odds ratio, CI confidence interval, BMI body mass index, Hs-CRP high-sensitivity-C-reactive protein, ALP alkaline phosphatase, iPTH intact parathyroid hormone
a Note that the odds ratio corresponds to a unit increase in the explanatory variable
Parameter Univariate analysis Multivariate analysis
ORa 95 % CIa P ORa 95 % CIa P
Predictor: hip fracture (N = 349)
 25(OH) D (≤50 nmol/L) 3.779 1.346–7.754 <0.0001 3.023 2.154–4.298 <0.0001
 Age 1.224 1.057–1.765 0.007 1.187 1.095–1.432 0.011
 Inadequate sun exposure 1.154 1.056–1.554 0.028 1.067 1.015–1.465 0.042
 History of falls during the last year 1.998 1.213–2.876 0.026 1.675 0.954–3.986 0.167
 Neurologic impairment 3.332 1.487–5.432 0.035 2.443 0.713–4.876 0.675
 Cognitive impairment 1.453 1.109–1.765 0.022 1.287 0.995–3.054 0.265
 Hs‑CRP 1.119 1.032–1.332 <0.001 1.075 1.024–1.242 0.001
 ALP 1.342 1.114–1.567 <0.001 1.211 1.068–1.243 0.009
 iPTH (≥6.8 pmol/L) 3.223 1.635–6.754 <0.0001 2.498 1.764–3.942 <0.001
Predictor: hip and upper‑limb fracture (N = 29)
 25(OH) D (≤50 nmol/L) 6.985 1.152–21.763 <0.0001 4.473 2.984–10.532 <0.0001
 Age 1.197 1.047–1.455 <0.001 1.088 1.027–1.133 <0.001
 BMI 1.332 1.142–1.487 0.006 1.225 1.087–1.392 0.009
 Inadequate sun exposure 1.176 1.032–1.543 0.010 1.082 1.012–1.544 0.022
 History of falls during the last year 2.221 1.317–2.678 0.012 1.785 0.932–3.576 0.113
 Neurologic impairment 2.543 1.943–4.581 0.036 1.476 0.911–3.632 0.455
 Cognitive impairment 1.665 1.232–2.043 0.020 1.332 0.992–2.874 0.321
 Hs‑CRP 1.228 1.053–1.489 0.005 1.112 1.044–1.432 0.015
 ALP 1.186 1.105–1.325 0.003 1.142 1.054–1.375 0.013
 iPTH (≥6.8 pmol/L) 4.214 2.536–8.433 <0.0001 3.254 1.998–7.984 <0.001
Page 6 of 8Fu et al. J Transl Med  (2015) 13:388 
possible confounders, the multivariate conditional logis-
tic regression analysis results suggested an increased 
risk of hip fracture when the serum 25(OH) D level was 
≤50 nmol/L (OR 3.023; 95 % CI 2.154–4.298; P < 0.001) 
and the serum iPTH level was ≥6.8  pmol/L (OR 2.498; 
95 % CI 1.764–3.942; P < 0.001).
25(OH) D and risk of hip and upper limb fracture
In this study, 29 hip fracture patients had concomitant 
upper limb fracture. The subgroup analysis results indi-
cated that the serum 25(OH) D levels were significantly 
(P  <  0.0001) higher in patients with hip fracture only 
compared with those who also had upper limb fracture 
[37.5 (IQR 29.0–48.5) nmol/L vs. 26.8 (IQR 17.0–39.5) 
nmol/L]. Among hip fracture patients who also had 
upper limb fracture, 85.9 and 68.8 % had vitamin D defi-
ciency and secondary hyperparathyroidism, respectively.
Furthermore, the optimal cutoff level of serum 25(OH) 
D as an indicator for the screening of hip and upper 
limb fracture was estimated to be 43.8 nmol/L based on 
the observation of the ROC curve; this yielded a sensi-
tivity of 73.8 % and a specificity of 67.4 %, with the AUC 
at 0.724 (95  % CI 0.621–0.823). Again, with an AUC of 
0.724, 25(OH) D showed a significantly greater discrimi-
natory ability compared with iPTH (AUC 0.647; 95 % CI 
0.564–0.743; P  <  0.01), high-sensitivity C-reactive pro-
tein (AUC 0.672; 95 % CI 0.557–0.785; P < 0.01), and age 
(AUC 0.623; 95  % CI 0.545–0.737; P  <  0.001). Table  2 
shows the ORs of the 25(OH) D and iPTH levels com-
pared with those of other clinical risk factors, as obtained 
through univariate conditional logistic regression analy-
sis. Similarly, when the measured serum 25(OH) D level 
was ≤50  nmol/L (OR 4.473; 95  % CI 2.984–10.532; 
P < 0.0001), the multivariate conditional logistic regres-
sion analysis showed a possibly increased risk of upper 
limb fracture. When the measured serum iPTH level was 
≥6.8 pmol/L (OR 3.254; 95 % CI 1.998–7.984; P < 0.001), 
an increased risk of hip fracture was also found.
Discussion
This study investigated the correlation between serum 
levels of 25(OH) D and iPTH, and accuracy in indicating 
the risk of hip and upper limb fracture in postmenopau-
sal women in a northern Chinese Han sample. Several 
reports have hypothesized a possible association between 
25(OH) D levels and the occurrence of hip fracture. 
However, the biggest advantage of this study was that it 
focused on the relationship of these two biomarkers with 
the occurrence of hip and upper limb fracture in a sam-
ple of ethnic northern Chinese patients. Few studies have 
linked the deficiency of such biomarkers to the occur-
rence of hip and upper limb fracture, and none have been 
done in a Chinese sample thus far.
The main finding in our study was that low serum 
25(OH) D and high iPTH levels indicate a higher risk 
of hip and upper limb fracture in the northern Chinese 
population. Serum 25(OH) D levels ≤50  nmol/L was 
associated with a 4.473-fold increase in risk of concomi-
tant upper limb fracture in postmenopausal women with 
hip fracture. Therefore, postmenopausal women with 
insufficient vitamin D may be at higher risk of sustain-
ing fractures. Consistent with our results, Oyen et al. [23] 
reported that vitamin D status had a significant inverse 
association with risk of low-energy distal radius frac-
ture in both women and men. In addition, Cauley et al. 
[24] found a negative correlation between decreased lev-
els of serum 25(OH) D and higher risk of hip fracture. 
Similarly, Holvik et al. [25] reported that subjects with a 
lower quartile level of serum 25(OH) D tended to have an 
increased risk of hip fracture. Burgi et al. [26] found that 
among white women, those with serum 25(OH) D levels 
in the highest quartile had half the risk of stress fracture 
compared with those in the lowest quartile (P  <  0.05). 
Interestingly, our findings support those results. How-
ever, contrasting findings have also been previously 
reported, with some authors arguing that no such signifi-
cant association exists after evaluating the possible inci-
dence of vertebral fracture [27]. Van et al. [28] reported 
that a serum level of 25(OH) D <30 nmol/L was associ-
ated with an increased risk of fractures in the youngest, 
but not in the oldest, age group after adjustment for con-
founders. Interestingly, Liu et  al. [29] found that there 
was an association between serum 25(OH) D levels and 
prognosis in Chinese postmenopausal women with hip 
fracture. Differences in the assay and sample test meth-
ods, subject populations, and analytic platforms used 
may explain the inconsistencies among studies. However, 
more research is necessary to clarify the difference.
In the United States, for example, more than half of 
women with serum vitamin D levels <30  nmol/L were 
found to have hip osteoporotic fracture [30]. Similarly, 
21.6 % of patients with hip fracture in Italy were found to 
have hypovitaminosis D [31]. In a study in Japan, Sakuma 
et  al. [10] reported that 62  % of patients with hip frac-
ture had hypovitaminosis D, whereas 19.4 % had second-
ary hyperparathyroidism (serum iPTH level >65 pg/mL). 
In Spain, 67 % of subjects with hip fracture had vitamin 
D levels less than 50  nmol/L, and 55  % had increased 
iPTH [32]. Furthermore, over 76.7 and 68.9 % of patients 
with hip fracture in India had vitamin D deficiency and 
secondary hyperparathyroidism, respectively [18]. In 
addition, Dhanwal et  al. [18] observed that there was a 
significant inverse correlation of iPTH level with 25(OH) 
D in patients with hip fracture. In contrast, an earlier 
study found no such correlation [33]. In our study, 72.3 % 
of subjects with hip fracture had vitamin D levels less 
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than 50  nmol/L, and 63.6  % had hyperparathyroidism. 
Similarly, in another Chinese sample, almost four-fifths 
of the hip fracture patients (78.9 %) had vitamin D defi-
ciency [29].
Severe vitamin D deficiency may be involved in the 
genesis of concomitant fractures. However, the biologi-
cal mechanism linking vitamin D deficiency with fracture 
is still unclear. Some biologically plausible mechanisms 
could be largely responsible for the risk of fracture. First, 
vitamin D deficiency may exert an effect on the reduc-
tion of muscle mass, which in turn may be the possible 
reason for the occurrence of hip fractures [34]. To be 
specific, vitamin D may play a part in maintaining the 
normal structural and optimal functions of skeletal mus-
cles, whereas vitamin D deficiency inevitably leads to loss 
of muscle mass and weakening of muscle function [5]. 
Besides, vitamin D deficiency may be closely associated 
with the production of abnormal levels of calcium-phos-
phorus, consequently resulting in diminished collagen 
matrix mineralization [35]. Jesudason et  al. [36] found 
that, in postmenopausal women, when the serum 25(OH) 
level <60  nmol/L, there might be an increase consider-
ing some bone resorption markers and ALP. By coinci-
dence, the present analysis showed a negative correlation 
between 25(OH) D and ALP. Second, another possible 
mechanism might be that vitamin D deficiency affects 
bone cells that express the vitamin D receptors (VDR), 
which has a possible effect on modulating the process 
of bone turnover [34]. In addition, similarly to another 
study, vitamin D deficiency has been found to contrib-
ute to the increased rate of falls, indicating a significant 
relationship between falls and VDR gene polymorphisms 
[37]. Further, in the experiment of McClung et  al. [38], 
two polymorphisms (Fok1 and Bsm1) in the VDR were 
observed to be significantly correlated with increased 
risk of stress fracture. Third, the results of our study sug-
gested that secondary hyperparathyroidism in vitamin 
D-depleted subjects may have a large influence on the 
incidence of impaired muscle function [14]. Lopes et al. 
[39] found that vitamin D deficiency-induced second-
ary hyperparathyroidism increased bone turnover and 
loss and therefore promoted the occurrence of fracture. 
Lastly, previous evidence has shown the existence of a 
significant relationship between vitamin D status and 
both fall pattern and choice reaction time. By definition, 
choice reaction time is a measurement that is especially 
useful in the reflection of neuroprotective mechanisms 
(e.g., central processing, cognition, motor response, etc.) 
[17, 34]. Previous works have supported the idea that by 
affecting bone tissue, severe vitamin D deficiency may 
increase the risk of multiple concomitant fractures [40].
This study has several limitations that should be taken 
into consideration. First, we were not able to examine 
other risk factors for fracture, including daily diet, physi-
cal activity, and physical performance. Vitamin D can 
improve the muscle function. Unfortunately, we did not 
test muscle function in this study. Second, we did not 
obtain data on the pre-fracture levels of serum 25(OH) 
D. In addition, we also did not obtain data on the dietary 
calcium and vitamin D intake, which might affect the lev-
els of 25(OH) D, ALP and iPTH in the serum [41]. Fur-
ther study about dietary calcium and vitamin D intake 
should be registered. Third, data collection toward fur-
ther estimation of bone fragility in our patients, such as 
measurement of bone mineral density and determination 
of the prevalence of vertebral fracture, was not carried 
out. Fourth, the serum 25(OH) D concentrations in male 
patients were not measured. Therefore, this study could 
not determine whether a similar association between 
lower serum 25(OH) D concentration and higher risk of 
stress fracture as that found in females exists in males; 
a previous study done by Ruohola et  al. [42] in Finland 
identified such an association in males. Fifth, we did 
not have the resources to measure the serum vitamin 
D–binding protein in our samples. Vitamin D–binding 
protein may play role in the process of fracture constant. 
Future studies with data on vitamin D–binding protein 
and vitamin D status are needed to further clarify the 
effect of each on fracture risk. Finally, the number of 
study subjects was small and not replicated. Hip fracture 
cases in our study perhaps do not represent all female hip 
fractures in Shandong because this hospital often treats 
complicated cases. Larger more extensive studies are 
needed to evaluate the risk factors of fracture in Chinese 
subjects to determine whether serum 25(OH) D is a reli-
able marker of fractures that can be used in clinical prac-
tice in other samples.
Conclusions
Vitamin D insufficiency and secondary hyperparathy-
roidism were found to be common problems in the sam-
ple of postmenopausal women who had experienced hip 
fracture. Monitoring the alterations in the serum levels of 
25(OH) D and iPTH could be applied clinically as inde-
pendent risk factors for hip fracture.
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